Published in Clin Infect Dis on May 22, 2013
Cryptococcus gattii infections. Clin Microbiol Rev (2014) 1.55
Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis (2014) 1.12
Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet Biol (2014) 1.02
Risks of "blind" automated identification systems in medical microbiology. J Clin Microbiol (2013) 0.90
Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis. PLoS Pathog (2015) 0.87
Phenotypic differences of Cryptococcus molecular types and their implications for virulence in a Drosophila model of infection. Infect Immun (2014) 0.86
Clinical implications of interferon-γ genetic and epigenetic variants. Immunology (2014) 0.85
Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest. PLoS One (2014) 0.84
Does the Capsule Interfere with Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Cryptococcus neoformans and Cryptococcus gattii? J Clin Microbiol (2015) 0.79
Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates. Front Microbiol (2016) 0.79
Extensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and Strategies. Infect Dis Rep (2014) 0.76
Cryptococcosis due to Cryptococcus gattii. Clin Infect Dis (2013) 0.76
Integrated therapy for HIV and cryptococcosis. AIDS Res Ther (2016) 0.75
Gastrointestinal cryptococcoma - Immune reconstitution inflammatory syndrome or cryptococcal relapse in a patient with AIDS? Med Mycol Case Rep (2015) 0.75
Antifungal clinical trials and guidelines: what we know and do not know. Cold Spring Harb Perspect Med (2014) 0.75
Post-infectious inflammatory response syndrome (PIIRS): Dissociation of T-cell-macrophage signaling in previously healthy individuals with cryptococcal fungal meningoencephalitis. Macrophage (Houst) (2015) 0.75
Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil. Eur J Clin Microbiol Infect Dis (2016) 0.75
Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev (2005) 14.71
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Melioidosis. N Engl J Med (2012) 6.94
The amsterdam declaration on fungal nomenclature. IMA Fungus (2011) 5.86
Peripheral intravenous catheter-associated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from two tertiary health services. Med J Aust (2013) 4.93
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis (2011) 3.98
Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology (2011) 3.13
Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei. J Clin Microbiol (2006) 2.94
Phylogeographic reconstruction of a bacterial species with high levels of lateral gene transfer. BMC Biol (2009) 2.94
Impact of endoscopic intervention in 100 patients with suspected postcholecystectomy bile leak. Gastrointest Endosc (2005) 2.69
Heavy snoring as a cause of carotid artery atherosclerosis. Sleep (2008) 2.63
SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis (2008) 2.56
The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis (2008) 2.39
Nonrandom distribution of Burkholderia pseudomallei clones in relation to geographical location and virulence. J Clin Microbiol (2006) 2.34
Acute rheumatic fever: a chink in the chain that links the heart to the throat? Lancet Infect Dis (2004) 2.33
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis (2008) 2.24
Population health significance of gestational diabetes. Diabetes Care (2003) 2.23
Clinical toxinology--where are we now? J Toxicol Clin Toxicol (2003) 2.23
Serum 25-hydroxyvitamin D and glycated haemoglobin levels in women with gestational diabetes mellitus. Med J Aust (2011) 2.20
Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous Northern Australia: epidemiology and outcomes. J Infect Dis (2009) 2.20
Scabies: a ubiquitous neglected skin disease. Lancet Infect Dis (2006) 2.18
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis (2013) 2.17
Phrenic nerve injury associated with high free right internal mammary artery harvesting. Ann Thorac Surg (2003) 2.04
What's hanging around your neck? Pathogenic bacteria on identity badges and lanyards. Med J Aust (2008) 2.03
Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis (2010) 1.94
Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. Clin Infect Dis (2006) 1.94
Isolates of Burkholderia pseudomallei from Northern Australia are distinct by multilocus sequence typing, but strain types do not correlate with clinical presentation. J Clin Microbiol (2004) 1.88
Prevention of peripheral intravenous catheter-related bloodstream infections: the need for a new focus. Med J Aust (2013) 1.85
Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg (2006) 1.82
A horizontal gene transfer event defines two distinct groups within Burkholderia pseudomallei that have dissimilar geographic distributions. J Bacteriol (2007) 1.82
Genomic islands from five strains of Burkholderia pseudomallei. BMC Genomics (2008) 1.82
Problems in diagnosing scabies, a global disease in human and animal populations. Clin Microbiol Rev (2007) 1.81
Murray Valley encephalitis: a review of clinical features, diagnosis and treatment. Med J Aust (2012) 1.77
Variables predicting change in benign melanocytic nevi undergoing short-term dermoscopic imaging. Arch Dermatol (2011) 1.74
Landscape changes influence the occurrence of the melioidosis bacterium Burkholderia pseudomallei in soil in northern Australia. PLoS Negl Trop Dis (2009) 1.74
Survey of simple sequence repeats in completed fungal genomes. Mol Biol Evol (2004) 1.73
Systematic review and consensus guidelines for environmental sampling of Burkholderia pseudomallei. PLoS Negl Trop Dis (2013) 1.72
Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother (2008) 1.69
Reduction of broad-spectrum antibiotic use with computerized decision support in an intensive care unit. Int J Qual Health Care (2006) 1.69
Hospitalised adult patients with pandemic (H1N1) 2009 influenza in Melbourne, Australia. Med J Aust (2010) 1.68
Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect (2010) 1.67
Echinocandin antifungal drugs in fungal infections: a comparison. Drugs (2011) 1.67
Within-host evolution of Burkholderia pseudomallei over a twelve-year chronic carriage infection. MBio (2013) 1.66
A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis (2007) 1.64
Ceftriaxone and cefotaxime use in Victorian hospitals. Med J Aust (2002) 1.63
Prevalence of antimicrobial-resistant organisms in residential aged care facilities. Med J Aust (2011) 1.62
Herpes simplex virus type 1 capsid protein VP26 interacts with dynein light chains RP3 and Tctex1 and plays a role in retrograde cellular transport. J Biol Chem (2004) 1.62
Sensitive and specific molecular detection of Burkholderia pseudomallei, the causative agent of melioidosis, in the soil of tropical northern Australia. Appl Environ Microbiol (2007) 1.62
Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis (2009) 1.61
Pulmonary manifestations of uncomplicated falciparum and vivax malaria: cough, small airways obstruction, impaired gas transfer, and increased pulmonary phagocytic activity. J Infect Dis (2002) 1.60
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2006) 1.59
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 1.58
Spatial variability in the pollen count in Sydney, Australia: can one sampling site accurately reflect the pollen count for a region? Ann Allergy Asthma Immunol (2004) 1.57
Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One (2011) 1.57
Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin Infect Dis (2011) 1.57
A review of nucleic acid-based diagnostic tests for systemic mycoses with an emphasis on polymerase chain reaction-based assays. Med Mycol (2002) 1.56
Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. PLoS One (2009) 1.56
Genetic diversity of Burkholderia pseudomallei isolates in Australia. J Clin Microbiol (2007) 1.56
Dengue and climate change in Australia: predictions for the future should incorporate knowledge from the past. Med J Aust (2009) 1.55
Irukandji syndrome case series from Australia's Tropical Northern Territory. Ann Emerg Med (2009) 1.54
Tandem repeat regions within the Burkholderia pseudomallei genome and their application for high resolution genotyping. BMC Microbiol (2007) 1.54
Leishmaniasis, an emerging imported infection: report of 20 cases from Australia. J Travel Med (2008) 1.51
Vibrio vulnificus and V. parahaemolyticus necrotising fasciitis in fishermen visiting an estuarine tropical northern Australian location. J Infect (2006) 1.51
Disease burden and health-care clinic attendances for young children in remote aboriginal communities of northern Australia. Bull World Health Organ (2008) 1.51
Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol (2008) 1.51
A very early-branching Staphylococcus aureus lineage lacking the carotenoid pigment staphyloxanthin. Genome Biol Evol (2011) 1.51
Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med (2008) 1.50
Clonality and recombination in genetically differentiated subgroups of Cryptococcus gattii. Eukaryot Cell (2005) 1.48
Accuracy of Burkholderia pseudomallei identification using the API 20NE system and a latex agglutination test. J Clin Microbiol (2007) 1.48
Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother (2004) 1.48
Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010. Emerg Infect Dis (2012) 1.48
Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. Clin Infect Dis (2008) 1.48
Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition. Infect Control Hosp Epidemiol (2008) 1.47
Duration of in vivo antimicrobial activity of antibiotic-impregnated cerebrospinal fluid catheters. Neurosurgery (2006) 1.45
Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis (2003) 1.44
Outcomes for Indigenous and non-Indigenous patients who access treatment for hepatitis C in the Top End of the Northern Territory. Med J Aust (2013) 1.43
Feline cryptococcosis: impact of current research on clinical management. J Feline Med Surg (2011) 1.43
Extreme weather events and environmental contamination are associated with case-clusters of melioidosis in the Northern Territory of Australia. Int J Epidemiol (2005) 1.43
Problematic linkage of publicly disclosed hand hygiene compliance and health care-associated Staphylococcus aureus bacteraemia rates. Med J Aust (2012) 1.43
Use of a single-nucleotide polymorphism genotyping system to demonstrate the unique epidemiology of methicillin-resistant Staphylococcus aureus in remote aboriginal communities. J Clin Microbiol (2006) 1.43
Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol (2012) 1.42
Pneumonia risk stratification in tropical Australia: does the SMART-COP score apply? Med J Aust (2010) 1.41
VNTR analysis of selected outbreaks of Burkholderia pseudomallei in Australia. Infect Genet Evol (2006) 1.40
Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins. Am J Trop Med Hyg (2006) 1.39
Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups. J Clin Microbiol (2002) 1.39
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.39
Improving burial practices and cemetery management during an Ebola virus disease epidemic - Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep (2015) 1.39
Development of a questionnaire to assess subjective vision score in myopes seeking refractive surgery. J Refract Surg (2004) 1.39